Pharmacological implications of lengthened in-utero exposure to nevirapine.
Given as a single dose to the mother during labour, nevirapine can protect the neonate from HIV-1 infection for up to 7 days. However, after maternal nevirapine therapy during pregnancy, neonatal plasma concentrations of nevirapine decline more rapidly, suggesting in-utero liver enzyme induction.
Taylor
G P
GP
Lyall
E G
EG
Back
D
D
Ward
C
C
Tudor-Williams
G
G
D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005312:Fetal Blood; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D007743:Labor, Obstetric; D008431:Maternal-Fetal Exchange; D008657:Metabolic Clearance Rate; D019829:Nevirapine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011247:Pregnancy
D019380:Anti-HIV Agents; D019829:Nevirapine